Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ).


Journal

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 19 02 2023
accepted: 14 03 2023
medline: 17 7 2023
pubmed: 21 3 2023
entrez: 20 3 2023
Statut: ppublish

Résumé

The Cluster Headache Impact Questionnaire (CHIQ) is a specific and easy-to-use questionnaire to assess the current impact of cluster headache (CH). The aim of this study was to validate the Italian version of the CHIQ. We included patients diagnosed with episodic CH (eCH) or chronic CH (cCH) according to the ICHD-3 criteria and included in the "Italian Headache Registry" (RICe). The questionnaire was administered to patients through an electronic form in two sessions: at first visit for validation, and after 7 days for test-retest reliability. For internal consistency, Cronbach's alpha was calculated. Convergent validity of the CHIQ with CH features and the results of questionnaires assessing anxiety, depression, stress, and quality of life was evaluated using Spearman's correlation coefficient. We included 181 patients subdivided in 96 patients with active eCH, 14 with cCH, and 71 with eCH in remission. The 110 patients with either active eCH or cCH were included in the validation cohort; only 24 patients with CH were characterized by a stable attack frequency after 7 days, and were included in the test-retest cohort. Internal consistency of the CHIQ was good with a Cronbach alpha value of 0.891. The CHIQ score showed a significant positive correlation with anxiety, depression, and stress scores, while showing a significant negative correlation with quality-of-life scale scores. Our data show the validity of the Italian version of the CHIQ, which represents a suitable tool for evaluating the social and psychological impact of CH in clinical practice and research.

Sections du résumé

BACKGROUND BACKGROUND
The Cluster Headache Impact Questionnaire (CHIQ) is a specific and easy-to-use questionnaire to assess the current impact of cluster headache (CH). The aim of this study was to validate the Italian version of the CHIQ.
METHODS METHODS
We included patients diagnosed with episodic CH (eCH) or chronic CH (cCH) according to the ICHD-3 criteria and included in the "Italian Headache Registry" (RICe). The questionnaire was administered to patients through an electronic form in two sessions: at first visit for validation, and after 7 days for test-retest reliability. For internal consistency, Cronbach's alpha was calculated. Convergent validity of the CHIQ with CH features and the results of questionnaires assessing anxiety, depression, stress, and quality of life was evaluated using Spearman's correlation coefficient.
RESULTS RESULTS
We included 181 patients subdivided in 96 patients with active eCH, 14 with cCH, and 71 with eCH in remission. The 110 patients with either active eCH or cCH were included in the validation cohort; only 24 patients with CH were characterized by a stable attack frequency after 7 days, and were included in the test-retest cohort. Internal consistency of the CHIQ was good with a Cronbach alpha value of 0.891. The CHIQ score showed a significant positive correlation with anxiety, depression, and stress scores, while showing a significant negative correlation with quality-of-life scale scores.
CONCLUSION CONCLUSIONS
Our data show the validity of the Italian version of the CHIQ, which represents a suitable tool for evaluating the social and psychological impact of CH in clinical practice and research.

Identifiants

pubmed: 36939946
doi: 10.1007/s10072-023-06758-0
pii: 10.1007/s10072-023-06758-0
pmc: PMC10345064
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2845-2851

Informations de copyright

© 2023. The Author(s).

Références

J Headache Pain. 2022 Mar 18;23(1):37
pubmed: 35303796
Front Neurol. 2020 Nov 10;11:597881
pubmed: 33240213
BMJ. 1992 Jul 18;305(6846):160-4
pubmed: 1285753
Cephalalgia. 2008 Jun;28(6):614-8
pubmed: 18422717
J Headache Pain. 2016 Dec;17(1):79
pubmed: 27596922
Lancet Neurol. 2018 Jan;17(1):75-83
pubmed: 29174963
Cephalalgia. 2020 Oct;40(11):1240-1249
pubmed: 32484060
Headache. 2012 Jan;52(1):99-113
pubmed: 22077141
Pharmacoeconomics. 2002;20(11):715-25
pubmed: 12201791
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Behav Res Ther. 1995 Mar;33(3):335-43
pubmed: 7726811
Curr Pain Headache Rep. 2013 Feb;17(2):313
pubmed: 23296640

Auteurs

Agnese Onofri (A)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 Coppito, 67100, L'Aquila, Italy.

Luigi Francesco Iannone (LF)

Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.

Antonio Granato (A)

Headache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy.

Gabriele Garascia (G)

Headache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy.

Luca Bartole (L)

Headache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy.

Paolo Manganotti (P)

Headache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy.

Catello Vollono (C)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Marina Romozzi (M)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Costanza Sottani (C)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Paolo Calabresi (P)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Cristina Tassorelli (C)

Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.

Grazia Sances (G)

Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.

Marta Allena (M)

Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.

Roberto De Icco (R)

Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.

Francesco De Cesaris (F)

Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.

Andrea Burgalassi (A)

Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.

Alberto Chiarugi (A)

Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.

Carlo Baraldi (C)

Department of Specialist Medicines, Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy.

Simona Guerzoni (S)

Department of Specialist Medicines, Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy.

Maria Pia Prudenzano (MP)

Headache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

Adriana Fallacara (A)

Headache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

Maria Albanese (M)

Regional Referral Headache Center, Neurology Unit, University Hospital Tor Vergata, 00133, Rome, Italy.
Department of Systems Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.

Innocenzo Rainero (I)

Headache Center, Department of Neuroscience "Rita Levi Montalcini", University of Torino, Turin, Italy.

Gianluca Coppola (G)

Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina, Italy.

Alfonsina Casalena (A)

Neurology Unit, "G. Mazzini" Hospital, Teramo, Italy.

Edoardo Mampreso (E)

Headache Centre, Neurology - Euganea, Health Unit, Padua, Padua, Italy.

Francesca Pistoia (F)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 Coppito, 67100, L'Aquila, Italy.

Paola Sarchielli (P)

Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.

Marisa Morson (M)

Italian Society for the Study of Headache (SISC), Rome, Italy.

Simona Sacco (S)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 Coppito, 67100, L'Aquila, Italy.

Pierangelo Geppetti (P)

Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.

Raffaele Ornello (R)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio 1 Coppito, 67100, L'Aquila, Italy. raffaele.ornello@univaq.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH